COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS
Objective. Data analysis of the register of patients with invasive aspergillosis (IA), which was founded in Saint Petersburg (1998–2017), and clinical case description of successful treatment of IA and mucormycosis with lungs involvement in a patient with Hodgkin’s lymphoma.Materials and methods. In...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2018-02-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689887445352448 |
|---|---|
| author | O. V. Shadrivova S. N. Khostelidi Yu. V. Borzova E. A. Desyatik A. G. Volkova M. O. Popova O. S. Uspenskaya O. S. Ruzhinskaya T. V. Shneyder T. S. Bogomolova S. M. Ignatyeva L. S. Zubarovskaya B. V. Afanasyev N. N. Klimko |
| author_facet | O. V. Shadrivova S. N. Khostelidi Yu. V. Borzova E. A. Desyatik A. G. Volkova M. O. Popova O. S. Uspenskaya O. S. Ruzhinskaya T. V. Shneyder T. S. Bogomolova S. M. Ignatyeva L. S. Zubarovskaya B. V. Afanasyev N. N. Klimko |
| author_sort | O. V. Shadrivova |
| collection | DOAJ |
| description | Objective. Data analysis of the register of patients with invasive aspergillosis (IA), which was founded in Saint Petersburg (1998–2017), and clinical case description of successful treatment of IA and mucormycosis with lungs involvement in a patient with Hodgkin’s lymphoma.Materials and methods. In the study were included 29 oncohematological patients with IA and mucormycosis. In control group were included 483 oncohematological patients with IA. We used criteria EORTS/MSG, 2008 for IA and mucormycosis diagnosis.Results. We identified that the combination of IA and mucormycosis significantly often develops in patients with acute lymphoblastic leukemia (32 %, р = 0.001), and allogeneic hematopoietic stem cells transplants (allo-HSCT) recipients (52 %, р = 0.001). In mixed-infection Aspergillus nidulans was frequent IA etiological agent (11 %, р = 0.001). The main mucormycosis etiological agents were Rhizopus spp. (45 %), Lichtheimia corуmbifera (20 %). The main sites of the localization were lungs (76 %), disseminated process and paranasal sinuses involvement were identified more frequently (45 % and 17 % (р = 0.0001; р = 0.002), respectively). Typical clinical feature of IA and mucormycosis combinations was hemoptysis (24 %, р = 0.008), radiological signs – lesions with cavities destruction (38 %), hydrothorax (29 %) and a “reverse halo” symptom (17 %). Antifungal therapy received 76 % of patients, surgery – 34 %.Conclusion. Mucormycosis was revealed in 5.7 % of patients with IA. The main risk factors for co-infection are allo-HSCT, long-term agranulocytosis, lymphocytopenia and glucocorticosteroid therapy. Overall 12 weeks survival in patients with mixed-infection was 38 %, significantly lower than in patients with IA (р = 0.005). An unfavorable prognosis factor was dissemination of mycotic infection (р = 0.009). |
| format | Article |
| id | doaj-art-436f6dc073e3410281dcb8045e9d15fd |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2018-02-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-436f6dc073e3410281dcb8045e9d15fd2025-08-20T03:21:28ZrusABV-pressОнкогематология1818-83462413-40232018-02-0112481710.17650/1818-8346-2017-12-4-8-17249COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTSO. V. Shadrivova0S. N. Khostelidi1Yu. V. Borzova2E. A. Desyatik3A. G. Volkova4M. O. Popova5O. S. Uspenskaya6O. S. Ruzhinskaya7T. V. Shneyder8T. S. Bogomolova9S. M. Ignatyeva10L. S. Zubarovskaya11B. V. Afanasyev12N. N. Klimko13I.I. Mechnikov North-Western State Medical UniversityI.I. Mechnikov North-Western State Medical UniversityI.I. Mechnikov North-Western State Medical UniversityI.I. Mechnikov North-Western State Medical UniversityI.P. Pavlov First Saint Petersburg State Medical UniversityI.P. Pavlov First Saint Petersburg State Medical UniversityLeningrad Regional Clinical HospitalI.P. Pavlov First Saint Petersburg State Medical UniversityLeningrad Regional Clinical HospitalI.I. Mechnikov North-Western State Medical UniversityI.I. Mechnikov North-Western State Medical UniversityI.P. Pavlov First Saint Petersburg State Medical UniversityI.P. Pavlov First Saint Petersburg State Medical UniversityI.I. Mechnikov North-Western State Medical UniversityObjective. Data analysis of the register of patients with invasive aspergillosis (IA), which was founded in Saint Petersburg (1998–2017), and clinical case description of successful treatment of IA and mucormycosis with lungs involvement in a patient with Hodgkin’s lymphoma.Materials and methods. In the study were included 29 oncohematological patients with IA and mucormycosis. In control group were included 483 oncohematological patients with IA. We used criteria EORTS/MSG, 2008 for IA and mucormycosis diagnosis.Results. We identified that the combination of IA and mucormycosis significantly often develops in patients with acute lymphoblastic leukemia (32 %, р = 0.001), and allogeneic hematopoietic stem cells transplants (allo-HSCT) recipients (52 %, р = 0.001). In mixed-infection Aspergillus nidulans was frequent IA etiological agent (11 %, р = 0.001). The main mucormycosis etiological agents were Rhizopus spp. (45 %), Lichtheimia corуmbifera (20 %). The main sites of the localization were lungs (76 %), disseminated process and paranasal sinuses involvement were identified more frequently (45 % and 17 % (р = 0.0001; р = 0.002), respectively). Typical clinical feature of IA and mucormycosis combinations was hemoptysis (24 %, р = 0.008), radiological signs – lesions with cavities destruction (38 %), hydrothorax (29 %) and a “reverse halo” symptom (17 %). Antifungal therapy received 76 % of patients, surgery – 34 %.Conclusion. Mucormycosis was revealed in 5.7 % of patients with IA. The main risk factors for co-infection are allo-HSCT, long-term agranulocytosis, lymphocytopenia and glucocorticosteroid therapy. Overall 12 weeks survival in patients with mixed-infection was 38 %, significantly lower than in patients with IA (р = 0.005). An unfavorable prognosis factor was dissemination of mycotic infection (р = 0.009).https://oncohematology.abvpress.ru/ongm/article/view/262invasive aspergillosismucormycosisaspergillusrhizopuslichtheimia corуmbiferarhizomucor |
| spellingShingle | O. V. Shadrivova S. N. Khostelidi Yu. V. Borzova E. A. Desyatik A. G. Volkova M. O. Popova O. S. Uspenskaya O. S. Ruzhinskaya T. V. Shneyder T. S. Bogomolova S. M. Ignatyeva L. S. Zubarovskaya B. V. Afanasyev N. N. Klimko COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS Онкогематология invasive aspergillosis mucormycosis aspergillus rhizopus lichtheimia corуmbifera rhizomucor |
| title | COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS |
| title_full | COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS |
| title_fullStr | COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS |
| title_full_unstemmed | COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS |
| title_short | COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS |
| title_sort | combination of invasive aspergillosis and mucormycosis in oncohematological patients |
| topic | invasive aspergillosis mucormycosis aspergillus rhizopus lichtheimia corуmbifera rhizomucor |
| url | https://oncohematology.abvpress.ru/ongm/article/view/262 |
| work_keys_str_mv | AT ovshadrivova combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT snkhostelidi combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT yuvborzova combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT eadesyatik combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT agvolkova combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT mopopova combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT osuspenskaya combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT osruzhinskaya combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT tvshneyder combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT tsbogomolova combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT smignatyeva combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT lszubarovskaya combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT bvafanasyev combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients AT nnklimko combinationofinvasiveaspergillosisandmucormycosisinoncohematologicalpatients |